================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported)  February 3, 2005

                               IMMUNOMEDICS, INC.
             (Exact name of registrant as specified in its charter)

             Delaware                   000-12104            61-1009366
   (State or other jurisdiction        (Commission        (I.R.S. Employer
         of incorporation)            File Number)       Identification No.)

  300 American Road, Morris Plains, New Jersey                 07950
    (Address of principal executive offices)                 (Zip Code)

Registrant's telephone number, including area code     (973) 605-8200

                                 Not Applicable
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities
    Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange
    Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
    Exchange Act (17 CFR 240.13e-4(c))

================================================================================



ITEM 5.02     DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF
              DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

              (d) On January 12, 2005, Immunomedics, Inc. (the "Company") filed
a Current Report on Form 8-K announcing that Don C. Stark has been appointed to
the Company's Board of Directors on January 10, 2005. At the Board of Directors
meeting on February 3rd, Mr. Stark was appointed to the Finance, and Research
and Development Committees.



                                   SIGNATURES

              Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                          IMMUNOMEDICS, INC
                                          -----------------------------------
                                          (Registrant)

Date February 7, 2005
                                          By:    /s/ Gerard G. Gorman
                                                 ----------------------------
                                          Name:  Gerard G. Gorman
                                          Title: Vice President, Finance and
                                                 Chief Financial Officer